ea0068p13 | Abstracts | UKINETS2019
Davis LM
, Nicou N
, Martin W
, Corcoran B
, Mulholland N
, Srirajaskanthan R
, Ramage J
, Wendler O
, Vivian G
Introduction: Perioperative mortality of patients who undergo heart valve surgery for carcinoid heart valve disease (CHVD) has been observed to be high (510%). We investigated whether peptide receptor radiotherapy (PRRT) with Lutetium-177 Dotatate can be used safely in patients with neuroendocrine neoplasms (NEN) and CHVD and if there is an associated survival advantage by reducing overall exposure of the valves to high doses of vasoactive peptides.<p class="abstext"...